FSD Pharma Inc. Files 6-K on Shareholder Meeting Results
Ticker: QNTM · Form: 6-K · Filed: Jul 30, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Jul 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, filing-update, corporate-governance
TL;DR
FSD Pharma filed its 6-K detailing shareholder meeting results from July 23rd.
AI Summary
FSD Pharma Inc. filed a Form 6-K on July 30, 2024, reporting on its Annual and General Special Meeting of Shareholders held on July 23, 2024. The filing includes a press release detailing the meeting's outcomes. Nathan Coyle, CFO, signed the report on July 29, 2024.
Why It Matters
This filing provides shareholders with official updates on corporate decisions and outcomes from the annual meeting, impacting their investment.
Risk Assessment
Risk Level: low — This is a routine filing reporting on a shareholder meeting, not indicating new financial distress or significant operational changes.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- July 23, 2024 (date) — Date of Annual and General Special Meeting
- July 29, 2024 (date) — Date of Report Signature
- July 30, 2024 (date) — Filing Date
FAQ
What type of report is FSD Pharma Inc. filing?
FSD Pharma Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
When was the Annual and General Special Meeting of Shareholders held?
The Annual and General Special Meeting of Shareholders was held on July 23, 2024.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
The Form 6-K was signed by Nathan Coyle, Chief Financial Officer.
What is the principal executive office address for FSD Pharma Inc.?
The principal executive office address is 199 Bay St., Suite 4000, Toronto, Ontario M5L 1A9, Canada.
What exhibit is included with this Form 6-K filing?
Exhibit 99.1 is included, which is a Press Release dated July 23, 2024, announcing the results of the Annual and General Special Meeting of Shareholders.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-07-29 21:04:41
Filing Documents
- fsd_6k.htm (6-K) — 10KB
- fsd_ex991.htm (EX-99.1) — 39KB
- fsd_ex991img1.jpg (GRAPHIC) — 6KB
- 0001654954-24-009569.txt ( ) — 59KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: July 29, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release dated July 23, 2024 – FSD Pharma Inc. Announces Results of Annual and General Special Meeting of Shareholders 3